Insider Transactions in Q4 2025 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,932
-9.13%
|
$79,164
$27.09 P/Share
|
|
Dec 30
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+15.74%
|
-
|
|
Dec 30
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,932
-4.33%
|
$79,164
$27.09 P/Share
|
|
Dec 30
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+8.14%
|
-
|
|
Dec 30
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,703
-6.27%
|
$504,981
$27.09 P/Share
|
|
Dec 30
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,278
+11.24%
|
-
|
|
Dec 30
2025
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,932
-8.46%
|
$79,164
$27.09 P/Share
|
|
Dec 30
2025
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+14.76%
|
-
|
|
Dec 30
2025
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,932
-7.27%
|
$79,164
$27.09 P/Share
|
|
Dec 30
2025
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+12.95%
|
-
|
|
Nov 12
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,600
$43.84 P/Share
|
|
Nov 12
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
|
Nov 11
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,454
-3.82%
|
$105,522
$43.78 P/Share
|
|
Nov 11
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,454
+3.68%
|
$61,350
$25.01 P/Share
|
|
Oct 30
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
200
-0.32%
|
$8,600
$43.81 P/Share
|
|
Oct 30
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.32%
|
$5,000
$25.01 P/Share
|
|
Oct 27
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,302
-5.08%
|
$141,986
$43.92 P/Share
|
|
Oct 27
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,302
+4.83%
|
$82,550
$25.01 P/Share
|
|
Oct 08
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,200
$41.0 P/Share
|
|
Oct 08
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|